Lipid-Polymer Conjugates for Phospholipase A2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lipid-conjugates have limitations in effectively inhibiting phospholipase A2 enzyme activity and providing broad protection against pathogenic and inflammatory processes, particularly in microbial infections and inflammatory disorders.
Innovation Solution
Development of low molecular weight lipid-polymer conjugates comprising glycosaminoglycans (GAGs) conjugated to phospholipids via amide or ester linkages, with specific mass ratios and molecular weights, to create compounds that can inhibit phospholipase A2 and modulate inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lipid-conjugates are used, then some protection against pathogenic processes is provided, but the scope of protection is limited and phospholipase A2 enzyme activity is not effectively inhibited
Solution Approach 1:
The patent creates lipid-polymer conjugates by chemically linking phospholipids to glycosaminoglycans, forming composite structures that combine the membrane-interacting properties of phospholipids with the bioactive properties of GAGs. This composite approach enables broader protection scope and more effective phospholipase A2 inhibition compared to simple lipid-conjugates, as the GAG portion provides additional functional capabilities while the phospholipid portion maintains membrane association.
Solution Approach 2:
The patent systematically varies molecular weight parameters of the GAG component (using low molecular weight GAGs with MW between 5-20 kD) and adjusts the mass ratio of phospholipid to GAG (from 0.25:15 to 5:15) to optimize both the scope of protection and the effectiveness of enzyme inhibition. These parameter changes enable tuning of the conjugate properties to achieve superior performance.
2Reliability
If lipid-conjugates are developed to provide broader protection, then scope of protection increases, but manufacturing complexity and structural definition become more challenging
Solution Approach 1:
The patent establishes specific parameter ranges to define the conjugate structure: GAG molecular weight between 5-20 kD and phospholipid to GAG mass ratio from 0.25:15 to 5:15. These defined parameters provide structural clarity and manufacturing guidance while enabling the broader protection scope, thus resolving the contradiction between complexity and performance.
3Reliability
If low molecular weight GAGs are used in the conjugates, then inflammatory response modulation improves, but manufacturing precision requirements increase
Solution Approach 1:
The patent specifies a molecular weight range of 5-20 kD for the GAG component, which balances the need for effective inflammatory modulation with the practical requirements of manufacturing. This range is precise enough to achieve the desired biological effect while being broad enough to allow for reasonable manufacturing tolerances. The defined mass ratio range (0.25:15 to 5:15) further provides manufacturing guidance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid-polymer conjugates effectively suppress inflammatory chemokines and cytokines, activate NF-κB, and promote wound healing, offering a broader scope of protection against microbial infections and inflammatory disorders.
Implementation Method 1
a first polymer and a second polymer coupled together to form a lipid-polymer conjugate
Data Source
AI summary
This invention provides low molecular weight lipid-GAG and phospholipids-GAG conjugates and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens.